Guangzhou RiboBio Partners with GE to Build Oligonucleotide CRO/CMO Facility

Guangzhou RiboBio signed a strategic partnership agreement with GE Healthcare Life Sciences to build Asia's largest oligonucleotide drug development and manufacturing facility in China . The partnership plans to provide a complete suite of services for global oligonucleotide drug companies. Founded in 2004, RiboBio offers nucleic acid products and services. In 2013, the company built its first cGMP oligonucleotide manufacturing facility. Oligonucleotide drugs, which target disease-specific genes, are being developed to treat cancer, infectious diseases and genetic diseases. More details.... Share this with colleagues: // //